DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Tesch H, Stoetzer O, Decker T. et al.
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Int J Cancer 2019;
144: 877-885
We do not assume any responsibility for the contents of the web pages of other providers.